Lung Cancer and Inflammation (R01)

The summary for the Lung Cancer and Inflammation (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Lung Cancer and Inflammation (R01): -Purpose:This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), invites research project grant applications for studies elucidating the role of the microenvironment and inflammation in lung carcinogenesis, as well as studies on the influence of these factors on the cell of origin and putative lung tumor cells. The main objective of this FOA is to stimulate research on lung cancer with a specific emphasis on the mechanisms precipitated by inflammatory changes in the lung microenvironment that are related to carcinogenesis. These investigations are expected to provide new insights into the early cell biological and molecular changes that may occur in lung cells, especially in putative lung stem cells, as they progress from a normal phenotype to a malignant one under the inflammatory influence. -Applications submitted in response to this FOA should emphasize mechanistic studies of inflammation in lung carcinogenesis and how these mechanisms may promote a selective advantage for developing lung tumor cells. The scope of research supported by this FOA could include animal models and cell culture models investigating potential mechanisms involved in the pathogenesis of lung cancer, as well as studies incorporating the analysis of human tissue to define the critical factors leading to lung carcinogenesis. -Applicants are encouraged to interact with and take advantage of the resources available through NCI supported research infrastructures such as the Mouse Models of Human Cancer Consortium, the Early Detection Research Network, and the Specialized Programs in Research Excellence.
Federal Grant Title: Lung Cancer and Inflammation (R01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-07-046
Type of Funding: Grant
CFDA Numbers: 93.39393.394
CFDA Descriptions: Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research
Current Application Deadline: No deadline provided
Original Application Deadline: Apr 24, 2007
Posted Date: Feb 13, 2007
Creation Date: Feb 13, 2007
Archive Date: May 24, 2007
Total Program Funding: $10,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.395 -- Cancer Treatment Research
Applicants Eligible for this Grant
For profit organizations other than small businesses Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments
Additional Information on Eligibility
Foreign institutions are eligible to apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021